Parthiv Mehta, MD
Radiation Oncology · Glenview, ILNPI 1962539759
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Boston Scientific at 57.3% of the total. 2025 is the largest year on record at $35,045, 4.3 times the $8,079 reported in 2019. Among radiation oncology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 510 payments — averaging $291.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$85K
- Bioprotect Medical, Inc.$13K
- Teleflex LLC$13K
- Palette Life Sciences, Inc.$12K
- Augmenix, Inc.$6K
- Novartis$4K
- plus $16K from 25 others
What the payments were for
- Consulting fees$48,25032%
- Speaking & faculty fees$80,30254%
- Travel & lodging$9,0166%
- Food & beverage$11,1367%
- Education$1740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 150 | $85,257 |
| Bioprotect Medical, Inc. | 16 | $13,120 |
| Teleflex LLC | 18 | $12,778 |
| Palette Life Sciences, Inc. | 15 | $11,981 |
| Augmenix, Inc. | 4 | $6,250 |
| Novartis | 11 | $3,559 |
| Angiodynamics, Inc. | 16 | $3,397 |
| Bayer | 32 | $3,242 |
| Photocure Inc | 5 | $2,924 |
| Isoray, Inc | 18 | $1,449 |
| Johnson & Johnson | 45 | $805 |
| Dendreon Pharmaceuticals LLC | 33 | $728 |
| Astellas Pharma US Inc | 24 | $568 |
| Blue Earth Diagnostics | 25 | $534 |
| Pfizer | 22 | $504 |
| Myovant Sciences Inc. | 20 | $498 |
| Sumitomo Pharma America, Inc. | 10 | $227 |
| Merck | 6 | $138 |
| Tolmar Pharmaceuticals, Inc. | 7 | $136 |
| Bard Peripheral Vascular, Inc. | 2 | $122 |
| Accord Healthcare, Inc. | 5 | $109 |
| Amgen | 4 | $99 |
| Sun Pharmaceutical Industries Inc. | 4 | $90 |
| Progenics Pharmaceuticals, Inc. | 4 | $87 |
| Myriad Genetic Laboratories, Inc. | 5 | $84 |
| AstraZeneca | 2 | $46 |
| Telix Pharmaceuticals | 2 | $44 |
| AbbVie | 2 | $36 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Clarus Therapeutics Inc. | 1 | $23 |
| Cardinal Health 414 LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SpaceOAR VUE System - 10mL$61,494
- BIOPROTECT BALLOON IMPLANT SYSTEM$12,977
- SpaceOAR System$11,298
- SPACEOAR VUE$10,549
- SPACEOAR$6,250
- Cysview$2,845
- Nanoknife$2,654
- Xofigo$1,317
- Nubeqa$1,149
- Brachytherapy Source$1,017
- GENERAL - THERAPIES$973
- AngioVac$584
- UroLift$550
- Barrigel$136
How this compares
$148,878 in reported general payments places this provider in the 95th percentile of 242 radiation oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 167 | $2,299,259 |
| OrgovyxRelugolix | 268 | $704,745 |
| ErleadaApalutamide | 22 | $338,702 |
| Abiraterone Acetate | 77 | $34,900 |
| Tamsulosin Hcl | 553 | $9,436 |
| Bicalutamide | 261 | $4,012 |
| Silodosin | 20 | $1,803 |
| Cefpodoxime Proxetil | 58 | $943 |
| Megestrol Acetate | 12 | $501 |
| Prednisone | 75 | $486 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $450 |
| Oxybutynin Chloride | 30 | $381 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 19 | $300 |
| Ciprofloxacin Hcl | 105 | $289 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 19 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $568 | $2,299,259167 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $227 | $704,745268 claims |
| Johnson & JohnsonErleada | $805 | $338,70222 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $23 | $34,90077 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 242 radiation oncology providers in Illinois.
Other radiation oncology in Glenview
- Ramji RajendranElk Grove Village$207K
- Brian BaumannSpringfield$204K
- Tamer RefaatFreeport$151K
- Sean PitrodaChicago$103K
- Aditya JulooriChicago$73K
- Steven ChmuraChicago$59K
- Marc PosnerLake Forest$55K
- William SmallChicago$54K
- Ken TatebeChicago$42K
- Sean SachdevChicago$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.